Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Alberta
$27,000.00
Reactivating Brain-Resident Immune Cells to Halt Glioblastoma Growth
FY 2025-26
Summary
Glioblastoma (GBM) is the most aggressive adult brain tumor, is highly resistant to radiotherapy and chemotherapy, and unlike many cancers does not respond to immunotherapy. Key to this failure is GBM’s immunosuppressive microenvironment, defined by few T cells and abundant macrophages, including resident microglia and infiltrating monocyte-derived macrophages. Although these cells have innate anti-tumor capacity, GBM reprograms them to support tumor growth.
Within this setting, GBM stem cells (GSCs) are regulators of immunosuppression and therapeutic resistance. GSCs survive standard therapies, shape the microenvironment, and display extensive single-cell and spatial heterogeneity as demonstrated by our group and others. Despite this progress, how diverse GSC states suppress macrophage anti-tumor activity is unknown. I hypothesize that GSCs use niche-dependent molecular pathways to inhibit macrophage function. To test this, I propose three aims:
Aim 1: Identify ligand-receptor interactions at GSC-macrophage interfaces by reanalyzing human and mouse GBM single-cell and spatial transcriptomic datasets.
Aim 2: Define functional roles of top candidates using spatially informed perturbation with plasmids encoding guide RNAs and protein epitopes detectable by multiplex immunofluorescence to assess how GSC gene loss alters macrophage responses.
Aim 3: Test whether genetic or pharmacologic blockade of key molecules restores macrophage anti-tumor activity and improves tumor control in mouse GBM models.
By uncovering how heterogeneous GSC populations suppress macrophages and identifying ways to reverse this suppression, this project addresses a central barrier to GBM immunotherapy and lays essential groundwork for therapies tailored to the brain’s immune environment.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572941
Name
Reid Elizabeth A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Reactivating Brain-Resident Immune Cells to Halt Glioblastoma Growth
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Gene Knockout; Glioblastoma; Immune Modulation; Immunology; Macrophage; Microglia; Oncology; Spatial Genomics; Tumor Immunology; Tumor Microenvironment
Abstract
Glioblastoma (GBM) is the most aggressive adult brain tumor, is highly resistant to radiotherapy and chemotherapy, and unlike many cancers does not respond to immunotherapy. Key to this failure is GBM’s immunosuppressive microenvironment, defined by few T cells and abundant macrophages, including resident microglia and infiltrating monocyte-derived macrophages. Although these cells have innate anti-tumor capacity, GBM reprograms them to support tumor growth.
Within this setting, GBM stem cells (GSCs) are regulators of immunosuppression and therapeutic resistance. GSCs survive standard therapies, shape the microenvironment, and display extensive single-cell and spatial heterogeneity as demonstrated by our group and others. Despite this progress, how diverse GSC states suppress macrophage anti-tumor activity is unknown. I hypothesize that GSCs use niche-dependent molecular pathways to inhibit macrophage function. To test this, I propose three aims:
Aim 1: Identify ligand-receptor interactions at GSC-macrophage interfaces by reanalyzing human and mouse GBM single-cell and spatial transcriptomic datasets.
Aim 2: Define functional roles of top candidates using spatially informed perturbation with plasmids encoding guide RNAs and protein epitopes detectable by multiplex immunofluorescence to assess how GSC gene loss alters macrophage responses.
Aim 3: Test whether genetic or pharmacologic blockade of key molecules restores macrophage anti-tumor activity and improves tumor control in mouse GBM models.
By uncovering how heterogeneous GSC populations suppress macrophages and identifying ways to reverse this suppression, this project addresses a central barrier to GBM immunotherapy and lays essential groundwork for therapies tailored to the brain’s immune environment.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Reid, Elizabeth A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~